Leanna M. Levine, Ph.D., President and CEO

Dr. Levine, founder, of ALine, Inc. is an entrepreneur, technologist, and inventor. She founded ALine in 2003, and has since grown the business through focused attention to the needs of the Life Science and In vitro diagnostic markets. She conceived and developed ALine’s unique and proprietary enabling fabrication platform that permits rapid prototyping and volume manufacture of complex microfluidic and lab on a chip devices. This has significantly lowered the cost of product development and enables the use of complex, higher functionality devices that are robust and disposable. Prior to founding ALine, Dr. Levine was involved in the development of bioanalytical technology to support life science research. She has 9 years experience in Monsanto's corporate R&D where her lab lead the industry in the application of fluorescence polarization for high throughput screening of enzyme targets, leading to a patent. In 1998 she joined Spectrum Laboratories as Director of Manufacturing and Product Development. During her tenure at Spectrum she developed a novel fabrication method for hollow fiber membranes, and improved the manufacture of Spectrum's hollow fiber membrane products. In 2001, she became Director of Applications Development at Nanostream, leading an effort to develop a microfluidic product for the life sciences laboratory for which she is a co-inventor. Dr. Levine earned her PhD at Washington University, St. Louis (1986), and her BS in Biochemistry and BA in German from the University of Missouri, Columbia, MO (1982). In 2003 she was a visiting scholar at the UCLA Anderson School of Business. In 2000 she was the chair of the Gordon Conference on Bioanalytical Sensors. She is the co-author on a dozen publications, and several patents.

Hal Lieberman, COO, through a contract with EXCELeration, Inc.

Mr. Lieberman has over thirty years of experience in health care management, marketing and consulting, in the areas of hospital administration, medical services, medical devices, diagnostic imaging, pharmaceuticals and bioinformatics. Previously, he was the CEO of HemaCare Corporation, the only publicly traded, for-profit blood services company to be licensed by the FDA and accredited by the American Association of Blood Banks. Mr. Lieberman was involved in the establishment of the USC Blood Center in Los Angeles and the Shandong Umbilical Cord Blood Center in Jinan, China. The blood management model he created while at HemaCare has become the outsourcing standard in the blood banking industry.

Joseph R. Stetter, Ph.D.

Dr. Stetter has been the founder of several start-up companies. As President and CEO of TRI, he managed the growth of the company to $1.5 million in annual sales through its merger with TSI, Inc. in 1993, and then continued as Division President until TRI was moved to Minnesota in January, 1997. Dr. Stetter has won several prestigious awards for his work in sensor research, instrument development, and technology transfer including the "2002 Entrepreneur of the Year" award given by TMAC (The Technology Management Association of Chicago).

Malcolm Morrison, Ph.D.

Dr. Malcolm Morrison has been involved in the start-up and successful growth of three companies, Chemical Systems, later purchased by Gelman Sciences, Microgon, and Spectrum Laboratories, Inc., Rancho Dominguez, CA, where he served as VP of Manufacturing Operations until retiring in 2002 His responsibilities have included product manufacturing, QA, engineering, and R&D. He was responsible for 12 FDA regulated class II medical devices and 420 FDA regulated MAF file products.

Antonio J. Ricco, Ph.D.

Dr. Ricco has a distinguished career in the development of core technologies for the commercialization of single-use plastic microfluidic array systems. He was the former senior director of Microtechnologies and Materials at ACLARA BioSciences, and is currently the Director of the National Center for Space Biological Technologies at Stanford University. Dr. Ricco is the co-author of over 200 presentations, 140 publications, and a dozen patents. He is a Fellow of The Electrochemical Society, past Chair of the Sensor Division of The Electrochemical Society, and a recipient of that division's Outstanding Achievement Award.

Lloyd Burgess, Ph.D.

Dr. Burgess directs a sensors and instrumentation group investigating new concepts in the development of integrated multi-component analysis systems for real-time industrial, biomedical and environmental monitoring applications. Major components of this effort involve integrated and guided wave optics and micro fluidics. At the University of Washington, he works closely with the Center for Process Analytical Chemistry, a NSF Industry/University Cooperative Research Center and the Molecular Life Sciences Center, one of the Centers of Excellence in Genomic Sciences program recently funded by the NIH. Dr. Burgess is an R&D 100 award winner, and has more than 100 research publications and patents in the area of chemical sensors.